Evidence map›Paper›PMID 37052463›Full record

ArticleGlycobiology2023

A 6-O-endosulfatase activity assay based on synthetic heparan sulfate oligomers.

Julius Benicky, Miloslav Sanda, Aswini Panigrahi, Jian Liu, Zhangjie Wang, Vijayakanth Pagadala, Guowei Su, Radoslav Goldman

Open access · bronzeAbstract read
In one paragraph

Article in Glycobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. UtilizingAmerican journal of physiology. Cell physiology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Heparan-6-Cancers · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Julius BenickyDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, United States.
Miloslav SandaDepartment of Biochemistry and Molecular & Cell Biology, Georgetown University, Washington, DC 20057, United States.
Aswini PanigrahiDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, United States.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States.
Zhangjie WangDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States.
Vijayakanth PagadalaGlycan Therapeutics, LLC, 617 Hutton Street, Raleigh, NC 27606, United States.
Guowei SuGlycan Therapeutics, LLC, 617 Hutton Street, Raleigh, NC 27606, United States.
Radoslav GoldmanDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, United States.
Georgetown University · USUniversity of North Carolina at Chapel Hill · US

Funding

O-glycoproteins in the progression of liver diseaseR01CA238455 · NCI · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2019 to 2023
$2.6M
Orbitrap Fusion Lumos ETDS10OD023557 · OD · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2017 to 2017
$1.1M
Development of a sensitive method to measure heparan sulfate 6-O-endosulfataseR43GM149008 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI SU, GUOWEI · 2023 to 2023
$350k
NCI NIH HHS R01 CA238455NIGMS NIH HHS R43 GM149008NIH HHS S10 OD023557
6 · The paper itself

Abstract

Sulf-2 is an extracellular heparan 6-O-endosulfatase involved in the postsynthetic editing of heparan sulfate (HS), which regulates many important biological processes. The activity of the Sulf-2 and its substrate specificity remain insufficiently characterized in spite of more than two decades of studies of this enzyme. This is due, in part, to the difficulties in the production and isolation of this highly modified protein and due to the lack of well-characterized synthetic substrates for the probing of its catalytic activity. We introduce synthetic HS oligosaccharides to fill this gap, and we use our recombinant Sulf-2 protein to show that a paranitrophenol (pNP)-labeled synthetic oligosaccharide allows a reliable quantification of its enzymatic activity. The substrate and products of the desulfation reaction are separated by ion exchange high-pressure liquid chromatography and quantified by UV absorbance. This simple assay allows the detection of the Sulf-2 activity at high sensitivity (nanograms of the enzyme) and specificity. The method also allowed us to measure the heparan 6-O-endosulfatase activity in biological samples as complex as the secretome of cancer cell lines. Our in vitro measurements show that the N-glycosylation of the Sulf-2 enzyme affects the activity of the enzyme and that phosphate ions substantially decrease the Sulf-2 enzymatic activity. This assay offers an efficient, sensitive, and specific measurement of the heparan 6-O-endosulfatase activity that could open avenues to in vivo activity measurements and improve our understanding of the enzymatic editing of the sulfation of heparan.

Indexed as

Heparan SulfateOligosaccharidesCell LineGlycosaminoglycansRecombinant ProteinsSulfotransferasesGlycosaminoglycansHeparan SulfateOligosaccharidesRecombinant ProteinsSulfotransferasesheparan 6-O-endosulfatase SULF2heparan sulfationSULF-2 enzymatic activitysynthetic heparan sulfate oligosaccharides

Identifiers

PMID37052463
PMCPMC10243761
OpenAlexW4365443882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.